Related to Studies Suggest that When It Comes to Drug Development Success, Size Matters

• Ascenta Enters Deal Potentially Worth $398M with Sanofi-Aventis
  
• Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal
  
• Gilead Steps Into Kinase Biology with Acquisition of CGI Pharmaceuticals for up to $120M
  
• Vitae Earns $14M from Boehringer Ingelheim with Start of Phase I Development
  
• ACT Raises $10M to Progress Preclinical Cancer Therapeutics
  
• Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF
  
• Bristol University Teams Up with Galapagos to Develop Neuropathic Pain Therapy
  
• BU Gets $1.6M NIH Award to Research Protein-Protein Interactions
  
• Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates
  
• Evotec and Argenta Sign New Drug Discovery Deals with Shionogi and Janssen
  
• SAFC Adds 50,000 Square Feet to Jerusalem Site to Bump Up Fermentation Capabilities
  
• Danish Consortium Gets DKK24M Funding to Identify Drugs against Epigenetic Factors
  
• BMS Initially Pays Exelixis $60M in Two Separate Deals
  
• Galenea Wins $4.5M NIMH Grant to Develop Small Molecule Schizophrenia Drugs
  
• Apeiron Teams Up with Evotec for R&D in Pain
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• EMA Launches Program to Help Firms with Advanced Therapeutics Negotiate Regulatory Maze
  
• Amgen’s Denosumab Cleared by FDA for Second Indication
  
• BI and F-Star Ally to Develop Antibody-Based Therapeutics against Multiple Targets
  
• Convergence and Selcia to Develop Ion Channel Drugs for Pain